Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + bortezomib + dexamethasone in relapsed/refractory multiple myeloma (transplant-ineligible)
ChiCTR-OPC-16010301Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Complete response rate and Overall response rate. Started Jan 2017; status: recruiting.
02
Drugs
tucidinostatbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-OPC-16010301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16010301.